Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?

摘要

Key Clinical Message A few cases of thyroid eye disease following alemtuzumab therapy have been described in patients with multiple sclerosis. Our patient is the first case of Graves’ orbitopathy after alemtuzumab conditioning for hematopoietic stem cell transplantation.